“The latest results show that PSA screening in this trial prevented 22 prostate cancer deaths per 10,000 men screened, compared to 14 deaths in the previous analysis. It also shows that the harms of ...
Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for PROTAC BCL6 degrader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback